DRRX stock forecast
Our latest prediction for DURECT Corp.'s stock price was made on the Feb. 6, 2020 when the stock price was at 1.63$.
In the short term (2weeks), DRRX's stock price should outperform the market by 3.93%. During that period the price should oscillate between -10.67% and +20.69%.
In the medium term (3months), DRRX's stock price should outperform the market by 2.60%. During that period the price should oscillate between -40.93% and +54.40%.Get email alerts
About DURECT Corp.
DURECT Corp. is a biopharmaceutical company, which engages in the research, development, and manufacturing of pharmaceutical products. The company products include alzet and lactel. Its pipeline includes DUR-928, which focuses on lipid homeostasis, inflammation, and cell survival; and POSIMIR, which is an analgesic product intended to deliver bupivacaine to provide pain relief after surgery. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.
At the moment the company generates 23M USD in revenues.
On its last earning announcement, the company reported a loss of -0.14$ per share.
The book value per share is 0.17$
Three months stock forecastFeb. 6, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|